Until recently, researchers and oncologists had placed lung cancer patients into two broad categories: those who would benefit from immunotherapy, and those who likely would not. Now, researchers, using artificial intelligence (AI) to analyze simple tissue scans, say they have discovered biomarkers that could tell doctors which lung cancer patients might actually get worse from immunotherapy.